Method for sedation with api-phytocomposition

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to experimental pharmacology, and can be used as a method for rat sedation with an api-phytocomposition. The method for rat sedation with the api-phytocomposition involving single and daily one-week administration of a sedative agent, which is administered intragastrically through a probe in a dose of 200 mg/kg of animal's body weight, wherein the api-phytocomposition contains honey, bee-bread, lime pollen, propolis, valerian extract in a ratio of 10:2:1:1:1, and represents an aqueous suspension.

EFFECT: method described above is effective for rat sedation and causes no side effects.

1 ex

 

The invention relates to medicine, in particular to experimental pharmacology.

Honey, bee bread, pollen Linden, propolis, Valerian - each individual component has a sedative effect, which manifests itself after a long course taking. When their combined use of possible synergies (mutual reinforcement effects of each component), resulting in sedative effect is faster and more pronounced.

Known method of sedation salicylate cobalt in the open field test (Yakovchuk So Century, Her Acting Century, Khusainova K. R. and other Psychotropic activity of salts of salicylic acid in terms of behavioral tests in rats // scientific notes of Taurida national University. C. I. Vernadsky. "Biology and chemistry". Tom 22 (61). 2009. №1. S. 134-138), which is characterized by the fact that the experiments were performed on 45 outbred rats-males weighing 200-250 g were divided into 3 groups of 15 rats. Testing was performed in the morning, once. Salicylate cobalt was dissolved in saline and were injected with intraperitoneally 30 min before the test dose of 40 mg/kg (amount of injection of 0.2 ml). Animals of control group received equivalent volumes of saline.

The main disadvantage of this method is that when you receive musk cobalt can be side effecty - allergic reactions (redness or skin rash, cough, stuffy nose and other); the mucosa of the gastrointestinal tract (abdominal pain, vomiting, gastrointestinal bleeding). Salicylates are not prescribed to patients with varicose expanded veins of the esophagus due to risk of bleeding.

Closest to the claimed solution is the way sedation dry extracts of Valerian, according to the description of experimental studies in the description of the invention to the patent of Russian Federation (RU 2223091, publ. 10.02.2004), which is that the experiment is carried out on laboratory animals according to the generally accepted test "open field" and "mink reflex" (Balykin B. C., Berezovskaya I. C. Comparative evaluation of methods approximate the response of rats in a Toxicological experiment // Pharmacology and toxicologia. 1976. 5. S. 636-638; Markel, A. A., Chugainov R. A. Method of complex registration behavioral and autonomic responses in rats during the test "open field" // Higher nervous activity. 1976. 6. S. 1314-1318). The experiments were carried out on outbred white rats-males. The tests were filmed before the introduction of the drug after a single weekly injection as freshly prepared and kept for more than a year of dry extracts. From experimental animals was formed four groups. Animals of the first group is s received as a standard drug Valerian tincture, the second group - extract 1, the third - extract 2, the fourth group of control. During the experiment evaluated the change in aggressiveness and tentative, exploratory and motor activity of animals.

The main disadvantage of this method is that when the intake of sodium bromide, part of the proposed drug possible phenomenon bromism: lethargy, weakness, slow speech, blurred vision, hearing loss, ataxia, apathy, weakness of memory, inflammation of mucous membranes, skin eruptions (acne bromica).

The task of the invention is a method of sedation IPA-phytocomplex containing honey, pollen, pollen Linden, propolis extract of Valerian.

The task is achieved in that in the method of sedation IPA-phytocomplex, including an experiment on laboratory animals according to the generally accepted test "open field with a single, and then daily introduction during the week, sedatives, and as a sedative use IPA-phytocomplex in the form of an aqueous suspension of honey, pollen, pollen Linden, propolis, Valerian ratio 10:2:1:1:1, at a dose of 200 mg/kg animal body weight, which is injected intragastrically (via probe).

The tests were filmed before the introduction of the IPA-creation of phyto compositions, after a single weekly injection. In the experiment included three groups of laboratory rats. Animals of the first group - intaktnye, the second group - with the introduction of the IPA-creation of phyto compositions, the third group - with the introduction of Valerian tincture (standard drug). During the experiment evaluated the change in aggression (AG) and estimated (OA), search (PA) and motor (YES) activity of animals.

Introduction to laboratory rats IPA-creation of phyto compositions leads to severe sedation due to synergism of the combination of honey, pollen, pollen Linden, propolis and Valerian extract, API-creation of phyto compositions.

The main advantage of the proposed method is the absence of side effects observed in the intake of sodium bromide, namely the phenomenon of bromism, as well as the natural origin of all components of the IPA-creation of phyto compositions.

The IMPLEMENTATION of the METHOD

The experience carried out on white rats-males weighing 200-250 g In the open-field test animals injected daily intragastrically (via probe) aqueous suspension of honey, pollen, pollen Linden, propolis, Valerian(10:2:1:1:1) at a dose of 200 mg/kg animal body weight. The tests were filmed before the introduction of the IPA-creation of phyto compositions, after a single weekly injection. In the experiment included three groups of laboratory rats. Animals of the first group is intact, the second group - with the introduction of the IPA-creation of phyto compositions, the third group - with the introduction of Valerian tincture (standard drug).

During the experiment evaluated the change in aggressiveness (the G) and estimated (OA), search (PA) and motor (YES) activity of animals.

SPECIFIC EXAMPLE

It is established that AG is reduced by 40% when administered infusions, and IPA-creation of phyto compositions. OA with the introduction of infusions reduced by 55%, whereas in animals treated with IPA-phytocomplex OA has not changed. PA animals treated with the tincture and IPA-phytocomplex decreased by 30%. YES treated as a tincture, and IPA-phytocomplex is reduced in 2 times.

Thus, IPA-a phytocomplex to the same extent as the tincture of Valerian reduces AG and YES. The positive is that IPA is a phytocomplex unlike tinctures no significant effect on OA, which contributes to the preservation of orientation in space. In General, IPA-a phytocomplex as tincture of Valerian has a sedative effect.

How sedation rats IPA-phytocomplex, including single and daily administration during the week sedatives, characterized in that as a sedative use IPA-phytocomplex in the form of an aqueous suspension at a dose of 200 mg/kg animal body weight, which is injected intragastrically through a tube, where IPA is a phytocomplex contains honey, bee bread, pollen Linden, propolis extract, Valerian extract in the ratio 10:2:1:1:1.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns using comenic acid potassium salt as a preventive and therapeutic antioxidant, stress- and neuroprotective agent in the amount of 2 to 8 mg per 1 kg of body weight daily on the empty stomach for 3 days.

EFFECT: agent possess high efficacy.

4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel pyranyl aryl methylbenzoquinazolinone compounds of formula (I), which are positive allosteric modulators of the M1 receptor and which can be used to treat diseases associated with the M1 receptor, such as Alzheimer's disease, schizophrenia, pain disorders or sleep disturbance. In formula (I) X-Y are selected from a group comprising (1) -O-CRARB-, (2) -CRARB-O-, (3) -CRARB-SRC-, (4) -CRARB-NRC- and (5) -NRC-CRARB-, where each RA and RB is a hydrogen atom, and RC is selected from a group comprising (a) hydrogen, (b) -C(=O)-C1-6alkyl, (c) -C1-6alkyl, (d) -C(=O)-CH2-C6H5, (e) -S(=O)2-C1-6 alkyl, R1 is a hydroxy group, R2 is selected from a group comprising (1) -phenyl, (2) - heteroaryl, where the phenyl or heteroaryl group R2 is optionally substituted; the rest of the values of the radicals are given in the claim.

EFFECT: obtaining novel pyranyl aryl methylbenzoquinazolinone compounds.

28 cl, 12 tbl, 37 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacology and concerns using comenic acid sodium salt as a preventive and therapeutic antioxidant, stress and neuroprotective agent in the amount of 1 to 4 mg per 1 kg of body weight daily on the empty stomach for 3 days.

EFFECT: invention provides the high clinical effectiveness.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to pharmacology and pharmaceutics, and concerns a sedative agent representing glycine immobilised on detonation nanodiamond particles 2-10 nm in size, and to a method for preparing it.

EFFECT: preparing the sedative agent.

4 cl, 7 dwg, 13 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses crystalline form of S-zopicone with spectrum of powder X-ray diffraction with application of Cu-Ka radiation, with characteristic peaks, expressed under conditions 20 approximately at 11.08°, approximately 12.38°, approximately 15.86°, approximately 17.88°, approximately 19.98°C and approximately 20.58°, DSC-thermogram, on which peak is observed approximately at 207.7°C, and infrared spectrum of absorption (IR) with characteristic peaks approximately at 3078 cm-1, approximately 2942-2838 cm-1, approximately 2790 cm-1, approximately 1716 cm-1, approximately 1463 cm-1, approximately 1372 cm-1 and approximately 757 cm-1.

EFFECT: claimed are: method of preparation of crystalline form of eszopiclone, pharmaceutical preparation and its application in manufacturing medication for treatment of sleep disorder.

8 cl, 8 dwg, 10 ex

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely therapy and neurology, and concerns a melatonin agonist therapy. As the above melatonin agonist, (lR-Trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide is administered in effective doses that provides treating or preventing disruption of circadian rhythm or sleep disturbance.

EFFECT: invention provides treating or preventing disruption of circadian rhythm or sleep disturbance.

9 cl, 2 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention provides new imidazo[1,2-b]pyridazine compounds covered by general structural formula (I) wherein the radicals and symbols have the values presented in the patent claim, and pharmaceutically acceptable salts thereof. The compounds of structural formula (I) are effective both for treating or preventing the diseases related to GABA receptor inhibition, anxiety, epilepsy, sleep disorders, including insomnia, and for inducing a sedative-hypnotic, anaesthetic effect, sleep and muscle relaxation.

EFFECT: there are presented methods for preparing the above compounds, and also intermediate compounds for preparing them.

21 cl, 4 tbl, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, and concerns a pharmaceutical composition for sublingual or buccal administration of the active ingredients of a low to poor water-solubility. As an active ingredient, the composition contains a solution of a hormone specified in a group consisting of melatonin, oestrogens, progesterone, testosterone and dihydrotestosterone in a pharmaceutically acceptable solvent, adsorbed or absorbed on particles of a pharmaceutically acceptable carrier. The invention also concerns methods for preparing and using the above pharmaceutical composition.

EFFECT: what is presented is the new composition for sublingual or buccal administration of the active ingredients of a low to poor water-solubility.

19 cl, 4 ex, 2 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is the use of 7-chlor-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-methyl-4,5-dihydro-imidazo[1,5-a][1,4]benzodiazepin-6-one or a pharmaceutically acceptable salt thereof for treating various types of insomnia (terminal one, insomnia in an individual under min. 65 years, for the relief of wakefulness after the beginning of a sleep, for the prolongation of total sleep time after the beginning of a sleep - versions), pharmaceutical compositions for the appropriate application (versions) and methods of treating the various types of insomnia (versions).

EFFECT: invention is effective in treating insomnia, maintaining the sleep, terminal insomnia, including in the aged; the compound has a short half-life, ie 3-4 hours (so it causes no residual sedative action), and improves the daily activity in the aged suffering diurnal drowsiness.

61 cl, 29 dwg, 10 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) and salts thereof wherein R1 represents -A11-A12-; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 3,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl containing methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine. Also, the invention also refers to a pharmaceutical composition possessing corticotrophin-releasing factor (CRF) receptor antagonist activity, containing a compound of formula (I), to a therapeutic/preventive agent, and a method of treating the diseases specified in the patent claim.

EFFECT: there are presented the compounds of formula (I) as corticotropin-releasing factor (CRF) receptor antagonists.

20 cl, 2 dwg, 2 tbl, 51 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, pharmaceutical industry, particularly to a method for increasing the physical endurance of a body exposed to ultraviolet irradiation. According to the method, an herbal tea containing nettle and plantain leaves and starwort herb taken in a ratio of 1:1:1 is administered orally into laboratory animals for 21 days daily at 5 ml/kg of body weight 20 minutes before the ultraviolet irradiation.

EFFECT: method provides the evident increase of the fatigue resistance in reducing the phytocorrection course and higher physical endurance.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and represents a composition adapted for oral administration, able to provide an anti-ageing skin effect, and containing the PPAR ligand containing omega-3 fatty acid specified in DHA, EPA or mixtures thereof, an agent binding to an oestrogen receptor, containing soya isoflavones, taking part in the post-translation collagen modification, representing vitamin C and a carotinoid; the composition contains one or more additional ingredients specified in antioxidants, flavouring agents, preserving agents and stabilising agents; the composition is substantially free from zinc and/or selenium, the composition is presented in the form of a capsule; provided the composition contains at least 0.01 wt % edible phospholipid emulsifying agents, a total amount of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in the composition makes more than 0.6 wt % or less than 0.024 wt %.

EFFECT: invention provides the synergetic effect on procollagen I, thereby ensuring the better positive anti-ageing skin effect.

13 cl, 2 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a composition possessing anti-inflammatory properties. The composition with the anti-inflammatory properties comprising a herbal extract prepared by extracting rose hip shells or rose hip shells and kernels in water or a mixture of water and ethanol followed by purifying and drying together with collagen hydrolysate. A method for preparing the composition. The composition with the anti-inflammatory properties. Using the composition for preparing a therapeutic agent or a biologically active food supplement or a balanced diet for preventing or for relieving symptoms accompanying joint complaints. The therapeutic agent with the anti-inflammatory properties containing the composition. The biologically active food supplement with the anti-inflammatory properties containing the composition. The balanced dietary product with the anti-inflammatory properties containing the composition.

EFFECT: agents possess the evident anti-inflammatory properties.

10 cl, 13 ex

FIELD: medicine.

SUBSTANCE: invention represents a natural antioxidant preparation technology for cosmetic applications. The presented method for preparing a biologically active extract of grape berries or secondary wine making products - husks of grapes - provides drying the raw material, grinding, mixing it with an extactant in a ratio of 1:2.

EFFECT: method provides producing the all-purpose antioxidant for all types of cosmetics rich in biologically active substances with the relatively simple technological process requiring no organic acids used.

1 cl, 2 ex, 1 tbl, 1 dwg

FIELD: chemistry.

SUBSTANCE: peat in a mixture with water is loaded into a dispersion chamber, then the dispersion chamber is pressurised, static pressure of 5-7 atm is supplied into it and the content of the chamber is processed by ultrasonic vibrations with a density of insonification not less than 50 W/cm2, providing the sound pressure on the mixture of peat with water for the preliminarily specified time, which exceeds the static pressure by 2-3 times. The invention also relates to biogel, obtained by the claimed method.

EFFECT: obtaining water-peat biogel with nanosized particles, in which useful substances do not lose their efficiency.

4 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a method for preparing an agent possessing an antiulcerogenic action. A method for preparing the agent possessing the antiulcerogenic action by extracting the aspen bark in 40% ethanol by the multi-step reverse-flow extraction followed by purification, vacuum concentration and drying in a vacuum chamber; the prepared dry extract is added with the Ludipress extract in the specific environment and used to fill solid gelatine capsules.

EFFECT: preparing the agent possessing the antiulcerogenic action.

15 dwg

FIELD: medicine.

SUBSTANCE: oral and dental care wipe comprises a hydrophilic cloth base and a therapeutic agent in the form of a bonding agent containing a composition of eucalyptus, mint, thyme and anise essential oils, an aqueous suspension of propolis dissolved in an aqueous solution of glycerol in the following proportions, wt %: eucalyptus 0.5-2; mint 1-20; thyme 1-3; anise 1-20, aqueous suspension of propolis 1-20; water with glycerol in equal proportions - the rest.

EFFECT: using the wipe promotes eliminating the pathogenic microflora, has the anti-inflammatory, repairing, deodorant and whitening effects.

FIELD: medicine, pharmaceutics.

SUBSTANCE: according to the present invention, a kit enhancing the look of eyelashes and containing an eyelash-enhancing composition, and a delivery system is proposed. The above delivery system contains a number of sterile disposable applicator brushes for the delivery of a sub-dose of bimatoprost containing 1 drop into a target area.

EFFECT: above eyelash-enhancing composition contains an effective amount of 0,03% bimatoprost.

13 cl, 3 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to an oral care composition and to a method for using the above composition for treating or preventing the dental calculus formation. The presented composition contains an anticalculous agent and an antibacterial agent containing a biphenol compound, which can be prepared of Magnolia officinalis; wherein the above composition is free from phosphate-containing anticalculous agents and polyphosphate-containing anticalculous agents; and wherein the anticalculous agents contain zinc oxide as a zinc ion source. The method of treating or preventing the dental calculus formation involves contacting the above composition with the oral cavity. What is also presented is a method for preventing the inhibition of the magnolia antibacterial agent absorption in the oral cavity from the above composition free from the polyphosphate-containing anticalculous agents or polyphosphate-containing anticalculous agents.

EFFECT: using the magnolia antibacterial agent in a combination with the anticalculous agents containing zinc oxide provides the improved absorption of the above antibacterial agent in the oral cavity in the absence of the polyphosphate-containing anticalculous agents or polyphosphate-containing anticalculous agents.

8 cl, 8 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: described are compositions for hair care, containing a β-aminoether compound in a cosmetically acceptable carrier, such as a spray or cream. Described is a compound of formula

:

in which n represents an integer number from 1 to 100; Z and Z′ together with atoms, which they are bound to, represent acrylate, methacrylate or amino-terminal groups; R2 represents C1-C20alkyl, possibly substituted with: hydroxyl, siloxyl, C1-C20alkoxygroup, substituted with hydroxyl, amino-C1-C20alkyl, substituted with from one to two hydroxyl groups, C6-C10aryl, substituted with C1-C20alkoxygroup, or C5-C10heteroaryl, containing one nitrogen heteroatom; and A contains a rubber fragment, which has a molecular weight in the range from approximately 1000 g/mol to approximately 10000 g/mol, selected from the group, consisting of butadiene and isoprene units. Also described is a cosmetic composition for hair, containing the said compound and cosmetically acceptable carrier. The application of the said cosmetic composition for scalp care is described.

EFFECT: obtaining the cosmetic composition for hair, increasing adhesion of hairs to each other, adding volume, texture and shape to the hair.

10 cl, 4 tbl, 17 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to an ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing. The ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing containing: bees wax, line seed oil, kerosene and visceral fat of pig taken in certain proportions.

EFFECT: ointment possesses a biostimulating effect, reduces the wound healing time with no post-therapeutic cicatrisation with good fixation, uniform distribution on the skin surface and ease of use.

9 dwg, 9 ex

Up!